Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| squamous epithelial cell | 4 studies | 50% ± 8% | |
| epithelial cell | 3 studies | 41% ± 8% |
Insufficient scRNA-seq data for expression of TMPRSS11D at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 76% | 3727.35 | 1095 / 1445 | 58% | 55.78 | 107 / 183 |
| uterus | 56% | 287.41 | 95 / 170 | 44% | 74.67 | 204 / 459 |
| tonsil | 0% | 0 | 0 / 0 | 96% | 129.96 | 43 / 45 |
| skin | 73% | 14.62 | 1326 / 1809 | 8% | 1.14 | 39 / 472 |
| prostate | 70% | 20.95 | 171 / 245 | 1% | 0.05 | 5 / 502 |
| bladder | 57% | 5.57 | 12 / 21 | 11% | 4.30 | 53 / 504 |
| lung | 29% | 1.64 | 170 / 578 | 33% | 18.03 | 382 / 1155 |
| thymus | 56% | 4.49 | 367 / 653 | 0% | 0 | 0 / 605 |
| pancreas | 42% | 3.25 | 138 / 328 | 4% | 0.23 | 8 / 178 |
| ovary | 45% | 3.89 | 81 / 180 | 0% | 0 | 0 / 430 |
| kidney | 43% | 2.33 | 38 / 89 | 2% | 0.23 | 15 / 901 |
| breast | 36% | 3.19 | 164 / 459 | 4% | 0.23 | 40 / 1118 |
| spleen | 39% | 2.49 | 93 / 241 | 0% | 0 | 0 / 0 |
| stomach | 37% | 14.52 | 134 / 359 | 1% | 0.03 | 3 / 286 |
| intestine | 34% | 2.10 | 330 / 966 | 3% | 1.83 | 18 / 527 |
| adrenal gland | 37% | 2.41 | 95 / 258 | 0% | 0 | 0 / 230 |
| liver | 35% | 2.00 | 79 / 226 | 0% | 0.03 | 2 / 406 |
| blood vessel | 33% | 2.42 | 439 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 26% | 2.18 | 241 / 929 | 0% | 0 | 0 / 0 |
| heart | 26% | 1.37 | 222 / 861 | 0% | 0 | 0 / 0 |
| muscle | 24% | 3.42 | 193 / 803 | 0% | 0 | 0 / 0 |
| adipose | 23% | 3.48 | 275 / 1204 | 0% | 0 | 0 / 0 |
| brain | 20% | 1.17 | 539 / 2642 | 0% | 0.01 | 2 / 705 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006508 | Biological process | proteolysis |
| GO_0007585 | Biological process | respiratory gaseous exchange by respiratory system |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0008233 | Molecular function | peptidase activity |
| GO_0004252 | Molecular function | serine-type endopeptidase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | TMPRSS11D |
| Protein name | Transmembrane serine protease 11D Transmembrane protease serine 11D (EC 3.4.21.-) (Airway trypsin-like protease) [Cleaved into: Transmembrane protease serine 11D non-catalytic chain; Transmembrane protease serine 11D catalytic chain] |
| Synonyms | HAT |
| Description | FUNCTION: May play some biological role in the host defense system on the mucous membrane independently of or in cooperation with other substances in airway mucous or bronchial secretions. Plays a role in the proteolytic processing of ACE2. Proteolytically cleaves and activates the human coronavirus 229E (HCoV-229E) spike glycoprotein which facilitate virus-cell membrane fusions; spike proteins are synthesized and maintained in precursor intermediate folding states and proteolysis permits the refolding and energy release required to create stable virus-cell linkages and membrane coalescence. Preferentially cleaves the C-terminal side of arginine residues at the P1 position of certain peptides, cleaving Boc-Phe-Ser-Arg-4-methylcoumaryl-7-amide most efficiently and having an optimum pH of 8.6 with this substrate. . |
| Accessions | O60235 H0Y8K7 ENST00000514868.1 ENST00000283916.11 |